Skip to main content

Table 1 FDA approved cancer immunotherapies (including immune checkpoint therapies and adoptive cell therapies)

From: Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy

Category Target Name Indication Source
Immune Checkpoint Therapeutic (ICI) PD-1 or PD-L1 Nivolumab (Opdivo) Various cancers (e.g., Melanoma, Non-Small Cell Lung Cancer, etc.) (1)
  Pembrolizumab (Keytruda) Various cancers (e.g., Melanoma, classical Hodgkin Lymphoma, Primary Mediastinal B-cell Lymphoma, etc.) (2)
  Atezolizumab (Tecentriq) Non-Small Cell Lung Cancer, Urothelial Carcinoma, and Breast Cancer (3)
  Cemiplimab (Libtayo) Cutaneous Squamous Cell Carcinoma (4)
  Durvalumab (Imfinzi) Non-Small Cell Lung Cancer (5)
  Avelumab (Bavencio) Merkel Cell Carcinoma, and Urothelial Carcinoma (6)
CTLA4 Ipilimumab (Yervoy) Melanoma, Renal Cancer, and MSI (7)
Chimeric Antigen Receptor
T-cell
Therapy (CAR-T)
CD19 Axicabtagene ciloleucel (Yescarta) Non-Hodgkin Lymphoma (8)
  Tisagenlecleucel (Kymriah) Non-Hodgkin Lymphoma (9)
  1. 1. http://chemocare.com/chemotherapy/drug-info/Nivolumab.aspx
  2. 2. https://www.keytruda.com
  3. 3. https://www.tecentriq.com
  4. 4. https://www.libtayohcp.com
  5. 5. https://www.imfinzi.com
  6. 6. https://www.bavencio.com/hcp
  7. 7. https://www.yervoy.com/YervoyGateway
  8. 8. https://www.yescarta.com
  9. 9. https://www.hcp.novartis.com